News | January 05, 2010

Bioresorbable Stent Shows Total Endothelialization at One Month

ART's polylactic acid bioabsorbable stent showed complete endothelialization within 30 days.

January 5, 2010 – In vivo and in vitro data released yesterday shows a new bioresorbable stent platform allows for complete endothelialization with little inflammation after one month.

These data on the Arterial Remodeling Technologies (ART) polylactic acid (PLA) stent were published in the current special supplement of EuroIntervention. The paper is authored by Antoine Lafont, M.D., Ph.D., head, interventional cardiology department, Georges Pompidou Hospital in Paris.

“The ART bioresorbable stent showed a remarkable ability to be deployed without recoil or breakage. At one month, endothelialization was 100 percent completed. Additionally important, inflammation, smooth muscle cell proliferation and collagen accumulation were equivalent to what typically occurs after balloon angioplasty,” said Dr. Lafont. “At six months, the ART stent was completely integrated into the artery wall, thus preventing any strut migration secondary to the bioresorption process. Further, peak PLA resorption did not result in an increase or even persistence of inflammation as it has been previously reported with other bioresorbable polymer stents. Finally, inflammation and smooth muscle cell proliferation were almost not detectable at six months, resulting in no hyperplasia — in other words, no in-stent restenosis.”

The data published in EuroIntervention show that ART’s bioresorbable stent provides the requisite initial mechanical scaffolding to resist recoil. Then, as it dissolves over time in, remodeling returns to the artery. The stent caused little inflammation in the artery, which the company said might eliminate the need for anti-proliferative drugs on the stent.

EuroIntervention Journal is an international, English language, peer-reviewed journal covering percutaneous and surgical cardiovascular interventions.

For more information:

Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init